Recent publications published by researchers at the MRC WIMM.
Menin inhibitors: a 2-in-1 defense versus AML immune evasion.
Chakraverty R., (2026), Blood, 147, 482 - 483
Advancing the Integration of 'Basic/Fundamental' and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress.
McLornan DP. et al, (2025), Bone Marrow Transplant, 60, 1303 - 1308
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
Zeiser R. et al, (2025), J Clin Oncol, 43, 2566 - 2571
Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study.
Hughes SE. et al, (2025), EClinicalMedicine, 84
Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial).
Chakraverty R. et al, (2025), BMJ Open, 15
Stem cell transplantation
Craddock C. and Chakraverty R., (2025), Hoffbrand S Postgraduate Haematology Eighth Edition, 719 - 744
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies.
Khatsuria F. et al, (2024), Lancet Oncol, 25, e476 - e488
How Important Is Unrelated Donor Human Leukocyte Antigen Disparity in the Post-Transplant Cyclophosphamide Era?
Chakraverty R., (2024), J Clin Oncol, 42, 3263 - 3265
Integrating patient and public involvement and engagement in translational medicine.
Shaw KL. et al, (2024), Lancet, 404, 828 - 831
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank.
McCracken C. et al, (2024), JACC CardioOncol, 6, 575 - 588
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS. et al, (2024), Lancet Rheumatol, 6, e339 - e351
The road to refractory graft-versus-host disease is paved with good intentions.
North D. and Chakraverty R., (2024), J Clin Invest, 134
Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity.
Cheminant M. et al, (2023), Blood, 141, 60 - 71
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
Schetelig J. et al, (2022), Bone Marrow Transplant, 57
CAR-T Cells and Recent Advances in Clinical Cellular Immunotherapy
Gu Y. et al, (2022), Practical Transfusion Medicine: Sixth Edition, 543 - 553
Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia
Sweeney C. et al, (2022), BLOOD, 140, 1576 - 1578
Graft-versus-host disease: a disorder of tissue regeneration and repair.
Chakraverty R. and Teshima T., (2021), Blood, 138, 1657 - 1665
Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation.
Marzolini MAV. et al, (2021), Transplant Cell Ther, 27, 682.e1 - 682.e12
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R. et al, (2021), N Engl J Med, 385, 228 - 238